Prestige Wealth Management Group LLC Has $5.25 Million Position in Johnson & Johnson (NYSE:JNJ)

Prestige Wealth Management Group LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 32,134 shares of the company’s stock after buying an additional 1,171 shares during the period. Johnson & Johnson comprises about 1.5% of Prestige Wealth Management Group LLC’s investment portfolio, making the stock its 18th biggest holding. Prestige Wealth Management Group LLC’s holdings in Johnson & Johnson were worth $5,250,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Johnson & Johnson by 2.3% in the 2nd quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after purchasing an additional 421,779 shares during the last quarter. FMR LLC lifted its stake in shares of Johnson & Johnson by 20.8% in the 2nd quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after purchasing an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after purchasing an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Johnson & Johnson by 0.3% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock worth $1,333,545,000 after acquiring an additional 24,505 shares during the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the transaction, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The disclosure for this sale can be found here. Insiders have sold a total of 277,886 shares of company stock worth $48,550,549 over the last ninety days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $168.74 on Friday. The firm has a market cap of $441.17 billion, a PE ratio of 23.50, a price-to-earnings-growth ratio of 3.28 and a beta of 0.56. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average price is $176.14 and its two-hundred day moving average price is $171.25.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Morgan Stanley cut their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 6th. Raymond James cut their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on shares of Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Bank of America dropped their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Finally, SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.